aztreonam + avibactam

Aztreonam + avibactam is a fixed-dose intravenous antibacterial combination marketed as **Emblaveo**. Aztreonam is a monobactam beta-lactam antibiotic that inhibits bacterial cell-wall synthesis through penicillin-binding protein 3, while avibactam is a reversible non-beta-lactam beta-lactamase inhibitor that protects aztreonam from hydrolysis by susceptible serine beta-lactamases. This combination is designed to retain activity against many multidrug-resistant aerobic Gram-negative pathogens, including organisms that co-produce metallo-beta-lactamases and serine beta-lactamases. It is approved in the United States with metronidazole for adults with complicated intra-abdominal infection and limited or no alternative treatment options; European authorization also includes complicated urinary tract infection including pyelonephritis, hospital-acquired pneumonia including ventilator-associated pneumonia, and certain aerobic Gram-negative infections in adults with limited treatment options. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217906Orig1s000lbl.pdf))

Brand names

Emblaveo

Other names

aztreonam + avibactamaztreonam-avibactamaztreonam/avibactam